BHV-4157 Clinical Study

A randomized, double-blind, placebo-controlled trial of adjunctive BHV-4157 in OCD

Contact us at ocdresearch@stanford.edu or 650-723-4095

About

Obsessive-Compulsive Disorder (OCD) is a chronic and disabling disorder that costs the economy over $2 billion annually and represents a significant public health problem. This multi-site study of a novel investigational drug for OCD is being conducted at Stanford.

Purpose: To understand whether a new drug, when used as adjunctive therapy, can bring about reduction in OCD symptoms.

This clinical study is listed in clinicaltrials.gov.

Participate

The Stanford Translational OCD Research Program is looking for adults 18-65 years old with OCD to take part in a study providing these possible benefits:

  • Free diagnostic evaluation
  • Receive once a day dosing of the study drug or a matching placebo for 3 months (randomization phase)
  • Receive once a day dosing of the study drug, after completing randomization phase, for 12 months (extension phase)
  • Compensation (randomization phase: up to $450, extension phase: up to $525)
  •  

You can participate if:

  •  You are 18-65 years old
  • You have a primary diagnosis of OCD
  • You have the capacity to provide informed consent
  • You currently experiencing non-response or inadequate response to their current Standard of Care (SOC) medication
  • You are currently on selective serotonin reuptake inhibitor (SSRI) or clomipramine treatment for an adequate duration and at an adequate dose
  • You are able to understand and agree to comply with the prescribed dosage regimens and procedures
  •  

You cannot participate if:

  • You have history of psychosurgery, Deep Brain Stimulation (DBS) or Electroconvulsive Therapy (ECT)
  • You have a psychiatric or medical conditions that makes participation unsafe
  • You are pregnant or nursing female
  •  

Duration of Study Involvement

  • Each individual will participate in a free diagnostic evaluation by experienced OCD clinicians
  • If eligible, the study will involve:
  •     Randomization phase:  up to 6 in-person visits and 2 visits via phone occuring over a span of 3 months
  •     Extension phase:             up to 7 in-person visits and 2 visits via phone occuring over a span of 12 months
  •  

Contact us

Address

401 Quarry Rd

Stanford, CA 94305-5715

E-mail

ocdresearch@stanford.edu

Phone Number

650-723-4095